Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.

Metzger P, Kirchleitner SV, Kluge M, Koenig LM, Hörth C, Rambuscheck CA, Böhmer D, Ahlfeld J, Kobold S, Friedel CC, Endres S, Schnurr M, Duewell P.

J Immunother Cancer. 2019 Nov 6;7(1):288. doi: 10.1186/s40425-019-0778-7.

2.

Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.

Helms MW, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar TR, Schnurr MM, Endres S, Wiederschain D, Scheidler S, Rothenfußer S, Brunner B, König LM.

Mol Cancer Ther. 2019 Sep 12. pii: molcanther.1262.2018. doi: 10.1158/1535-7163.MCT-18-1262. [Epub ahead of print]

PMID:
31515294
3.

Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.

Wiedemann GM, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, Anz D.

Pathology. 2019 Oct;51(6):586-592. doi: 10.1016/j.pathol.2019.06.001. Epub 2019 Aug 21.

PMID:
31445808
4.

CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.

Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D.

J Exp Med. 2019 May 6;216(5):1170-1181. doi: 10.1084/jem.20170277. Epub 2019 Mar 25.

5.

CCL1 is a major regulatory T cell attracting factor in human breast cancer.

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.

BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8.

6.

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.

Metzger P, Kirchleitner SV, Koenig LM, Hörth C, Kobold S, Endres S, Schnurr M, Duewell P.

Sci Rep. 2018 Jun 11;8(1):8810. doi: 10.1038/s41598-018-27125-6.

7.

Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.

Mak'Anyengo R, Duewell P, Reichl C, Hörth C, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer C.

JCI Insight. 2018 Mar 8;3(5). pii: 96322. doi: 10.1172/jci.insight.96322.

8.

Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.

Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S, Kobold S.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12994-12999. doi: 10.1073/pnas.1705165114. Epub 2017 Nov 17.

9.

Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.

Wiedemann GM, Knott MM, Vetter VK, Rapp M, Haubner S, Fesseler J, Kühnemuth B, Layritz P, Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D.

Oncoimmunology. 2016 Apr 25;5(9):e1175794. eCollection 2016.

10.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

Oncoimmunology. 2016 May 31;5(7):e1189051. doi: 10.1080/2162402X.2016.1189051. eCollection 2016 Jul.

11.

FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.

Freier CP, Kuhn C, Endres S, Mayr D, Friese K, Jeschke U, Anz D.

Anticancer Res. 2016 Jun;36(6):3139-45.

PMID:
27272839
12.

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.

Oncoimmunology. 2015 Oct 29;5(3):e1105428. eCollection 2016 Mar.

13.

Immunotherapy in Tumors.

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review.

14.

Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery.

Heidegger S, Gössl D, Schmidt A, Niedermayer S, Argyo C, Endres S, Bein T, Bourquin C.

Nanoscale. 2016 Jan 14;8(2):938-48. doi: 10.1039/c5nr06122a.

PMID:
26659601
15.

Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive Factor.

Heidegger S, Jarosch A, Schmickl M, Endres S, Bourquin C, Hotz C.

PLoS One. 2015 Nov 13;10(11):e0142523. doi: 10.1371/journal.pone.0142523. eCollection 2015.

16.

Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.

Duewell P, Beller E, Kirchleitner SV, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.

Oncoimmunology. 2015 Apr 14;4(10):e1029698. eCollection 2015 Oct.

17.

Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.

Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.

Cancer Res. 2015 Nov 1;75(21):4483-93. doi: 10.1158/0008-5472.CAN-14-3499. Epub 2015 Oct 2.

18.

TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection.

Hotz C, Roetzer LC, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C.

J Immunol. 2015 Nov 1;195(9):4387-95. doi: 10.4049/jimmunol.1500079. Epub 2015 Sep 21.

19.

Reply.

Hoffmann F, Endres S, Rothenfusser S.

Hepatology. 2016 Mar;63(3):1062-3. doi: 10.1002/hep.27955. Epub 2015 Jul 23. No abstract available.

PMID:
26106015
20.

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.

Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger JC, Schnurr M, Endres S, Rothenfußer S.

J Natl Cancer Inst. 2015 Jun 23;107(8). pii: djv146. doi: 10.1093/jnci/djv146. Print 2015 Aug.

Supplemental Content

Loading ...
Support Center